PharmaVOICE
117 FOLLOWERS
PharmaVOICE is a resource for life-sciences executives and other healthcare-service related professionals. The primary research are made of by executive and corporate management from pharmaceutical, biotechnology, drug delivery, marketing communications, clinical services, contract research, drug development, and information technology companies, as well as other industry sectors.
PharmaVOICE
11h ago
Citius Pharmaceuticals CEO Leonard Mazur has personally invested $22.5 million into the company, which is fast approaching a potential turning point ..read more
PharmaVOICE
23h ago
A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation ..read more
PharmaVOICE
3d ago
The presumptive Democratic nominee has a long history of taking on pharma over drug prices and supporting women’s healthcare access ..read more
PharmaVOICE
4d ago
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups. ..read more
PharmaVOICE
4d ago
BARDA director Gary Disbrow explains the agency’s focus, how companies can get their “foot in the door” and why platforms are so important for preparedness ..read more
PharmaVOICE
5d ago
With great potential in cell and gene therapies, there are still plenty of barriers to getting the breakthroughs to patients.
..read more
PharmaVOICE
1w ago
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success ..read more
PharmaVOICE
1w ago
The pharma company is tackling the “stiff person syndrome” that afflicts Celine Dion in a phase 2 trial for its lead CAR-T candidate ..read more
PharmaVOICE
1w ago
With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows that every step counts ..read more
PharmaVOICE
1w ago
Ensho Therapeutics just launched but is already generating buzz with its phase 2-ready clinical program for inflammatory bowel disease ..read more